Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...
Vivani Medical, Inc. (NASDAQ:VANI) announced that the U.S. FDA has cleared its Investigational New Drug Application for NPM-119, paving the way for the commencement of the LIBERATE-1 Phase 1 trial.
Case involving a 2-rod subdermal contraceptive implant mistaken for a 1-rod device demonstrates the importance of delivering culturally competent care. A 37-year-old woman of Pacific Island descent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results